Gastric Cancer

P=N/A, N=73, Completed, Nantes University Hospital | Active, not recruiting --> Completed | N=110 --> 73

P=N/A, N=20, Not yet recruiting, Case Comprehensive Cancer Center

P2, N=31, Recruiting, Guang'anmen Hospital of China Academy of Chinese Medical Sciences

LAIR1 represents a novel prognostic indicator and functional oncoprotein that facilitates GC progression and metastasis, possibly through modulation of the EMT pathway. These findings underscore its potential as a therapeutic target in GC.

The construction of DSL risk prediction models with RF can facilitate more effective clinical management. Furthermore, our findings indicate that DSL affects RFS after gastric cancer surgery.

Drug sensitivity prediction suggested differential therapeutic vulnerabilities, with high-risk patients showing increased predicted sensitivity to JAK inhibitors, dasatinib, and nutlin-3a. An LLPS-related three-gene RiskScore identifies GC subgroups with different prognosis, immune features, and therapeutic sensitivity.

In silico knockout analysis demonstrated that these five model genes played critical roles in metabolic reprogramming, cell cycle regulation, and extracellular matrix modulation. By integrating multi-algorithm diagnostic modeling with in silico gene knockout analysis, this study systematically identified key FRGs and regulatory networks in GC.

We identified miR-1287-5p as a novel predictor of LNM in GC patients. We established a nomogram model for predicting LNM in GC patients, and evaluated its performance in a supportive cohort.

Accumulating evidence highlights the potential role of FXYD3 as an emerging biomarker with relevance to diagnosis, prognosis, and therapeutics. This review provides an overview of FXYD3's role in cancer biology from translational relevance to its potential as a diagnostic, prognostic, and therapeutic target.

CELF2 is a tumor suppressor that promotes the level and susceptibility of ferroptosis in STAD cells by targeting SLC7A11. Implications: This study offers valuable molecular insights for the development of ferroptosis-targeted therapies for STAD.

This chemokine-based signature provides clinically relevant prognostic stratification in GC and implicates the CXCL8-macrophage axis as a potential therapeutic target.

Administration of anti-IL-17A antibodies to CD200R1-deficient mice normalized thrombin-antithrombin complexes in vivo, and a meta-analysis of human COVID-19 studies showed reduced pulmonary thromboembolism in those on anti-IL-17A antibodies. These findings highlight the utility of plasma proteomics to improve prediction of thrombosis in patients with cancer and to identify unanticipated mechanistic insights and therapeutic targets in thrombo-inflammatory disease.